3-HO-PCP
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H25NO |
| Molar mass | 259.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Hydroxyphencyclidine (3-HO-PCP) is a dissociative anesthetic that has been sold online as a designer drug.[1] 3-HO-PCP binds to the NMDA and opioid receptors.[2][3][4][5][6][7][8][9]
On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a reportabout methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-HO-PCP.[10]
See also
References
- ^ Morris, H.; Wallach, J. (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6: 614–632. doi:10.1002/dta.1620. PMID 24678061.
{{cite journal}}: Cite has empty unknown parameter:|1=(help) - ^ Yossef Itzhak (1986). "High and low affinity psychotomimetic opioid binding sites: characterization by a novel 3H-PCP-analog" (PDF). NIDA Research Morograph. 75: 173–176. PMID 2828967.
- ^ J. M. Kamenka, B. Chiche, R. Goudal, P. Geneste, J. Vignon, J. P. Vincent, M. Lazdunski (April 1982). "Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl)piperidine derivatives". Journal of Medicinal Chemistry. 25 (4): 431–435. doi:10.1021/jm00346a019. PMID 6279847.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Yossef Itzhak, Asher Kalir, Yosef Sarne (July 1981). "On the opioid nature of phencyclidine and its 3-hydroxy derivative". European Journal of Pharmacology. 73 (2–3): 229–233. doi:10.1016/0014-2999(81)90097-2. PMID 6273187.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Nicole Johnson, Yossef Itzhak, Gavril W. Pasternak (June 1984). "Interaction of two phencyclidine opiate-like derivatives with 3H-opioid binding sites". European Journal of Pharmacology. 101 (3–4): 281–284. doi:10.1016/0014-2999(84)90171-7. PMID 6088255.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Yossef Itzhak (1988). "Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites". Life Sciences. 42 (7): 745–752. doi:10.1016/0024-3205(88)90646-7. PMID 2893238.
- ^ Yossef Itzhak (April 1987). "[3H]PCP-3-OH and (+)[3H]SKF 10047 binding sites in rat brain membranes: evidence of multiplicity". European Journal of Pharmacology. 136 (2): 231–234. doi:10.1016/0014-2999(87)90715-1. PMID 3036548.
- ^ Yossef Itzhak, Mabda Khouri (February 1988). "Regulation of the binding of σ- and phencyclidine (PCP)-receptor ligands in rat brain membranes by guanine nucleotides and ions". Neuroscience Letters. 85 (1): 147–152. doi:10.1016/0304-3940(88)90445-4. PMID 2834673.
- ^ Toshihito Suzuki, Toshifumi Yamamoto, Takafumi Hori, Shuzo Abe, Takashi Moroji, Hiroyasu Shiraishi, Takehiko Ito, Ing Kang Ho (1995). "Quantitative autoradiographic localization of [3H]3-OH-PCP (1-(1(3-Hydroxyphenyl)cyclohexyl)piperidine) binding sites in rat brain". Brain Research Bulletin. 37 (4): 431–435. doi:10.1016/0361-9230(95)00005-4. PMID 7620917.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "(ACMD) Methoxetamine Report (2012)" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2015-06-24.
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |